Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The effect of nevirapine once-daily dosing on the pharmacokinetics of methadone and its main metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, was evaluated in ten HIV positive patients on stable methadone therapy. Nevirapine 200 mg once daily was administered orally from day 1 to day 14. On day 15, nevirapine dose was increased to 400 mg once daily for the following 7 days of study and thereafter. On days 0, 8, and 22, concentration-time profiles of methadone and its metabolite were collected after methadone intake. Noncompartmental pharmacokinetic analysis was performed. Pharmacokinetic parameters obtained on days 8 and 22 were compared with those obtained before nevirapine administration. After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study. After 7 days with nevirapine 200 mg, methadone area under the plasma concentration time curve (AUC) and maximum concentration (Cmax) values were reduced by 63.3% and 55.2%, respectively. Switching to high dose nevirapine (400 mg once daily) did not result in a greater decrease in the methadone AUC and Cmax compared with 200 mg nevirapine. None of the noncompartmental pharmacokinetic parameters of methadone metabolite evidenced statistically significant differences across the three study periods. The decrease in methadone AUC and Cmax administrated once daily was similar to that seen in other studies with nevirapine administrated twice daily, suggesting that the degree of induction of methadone metabolism by nevirapine is similar for both dosing regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Murphy RL, Montaner J (1996) Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 5:1183–1199

    Article  CAS  Google Scholar 

  2. Anonymous (1996) Nevirapine tablets, Viramune tablets. Summary basis of approval equivalent. FDA Summary Basis of Approval

  3. Havlir D, Cheesman SH, McLaughlin W et al (1995) High dose nevirapine: safety, pharmacokinetics, and antiviral effects in patients with HIV infection. J Infect Dis 171:537–545

    PubMed  CAS  Google Scholar 

  4. Riska P, Lamson M, MacGregor T et al (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895–901

    PubMed  CAS  Google Scholar 

  5. Stocker H, Kruse G, Kreckel P et al (2004) Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agent Chemother 48:4148–4153

    Article  CAS  Google Scholar 

  6. Dole V, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193:646–650

    PubMed  CAS  Google Scholar 

  7. NIH Consensus Conference (1998) Effective medical treatment of opiate addiction. JAMA 280:1936–1943

    Article  Google Scholar 

  8. Kreek MJ, Vocci FJ (2002) History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 23:93–105

    Article  PubMed  Google Scholar 

  9. Iribarne C, Berthou F, Baird S et al (1996) Involvement of cyctochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365–373

    Article  PubMed  CAS  Google Scholar 

  10. Wang JS, DeVane CL (2003) Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos 31:742–747

    Article  PubMed  CAS  Google Scholar 

  11. Gerber JG, Rhodes RJ, Gal J (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16:36–44

    Article  PubMed  CAS  Google Scholar 

  12. Beckett AH, Taylor JF, Casy AF, Hassan MM (1968) The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol 20:754–762

    PubMed  CAS  Google Scholar 

  13. Altice FL, Friedland GH, Cooney EL (1999) Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13:957–962

    Article  PubMed  CAS  Google Scholar 

  14. Heelon MW, Meade LB (1999) Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19:471–472

    Article  PubMed  CAS  Google Scholar 

  15. Pinzani V, Faucherre V, Peyriere H, Blayac JP (2000) Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 34:405–407

    Article  PubMed  CAS  Google Scholar 

  16. Clarke SM, Mulcahy FM, Tjia J et al (2001) Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 33:1595–1597

    Article  PubMed  CAS  Google Scholar 

  17. van Leth F, Phanuphak P, Ruxrungtham K et al (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363:1253–1263

    Article  PubMed  CAS  Google Scholar 

  18. van Heeswijk RP, Veldkamp AI, Mulder JW et al (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14:77–82

    Article  Google Scholar 

  19. Crommentuyn KM, Huitema AD, Brinkman K, van der Ende ME, de Wolf F, Beijnen JH, Athena study (2001) Nevirapine once daily versus twice daily: implications for drug-drug interactions. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2–4; Noordwijk, Holland. http://www.natap.org/2001/2ndworkshop/nvp_oncedaily041601.htm

  20. Torrens M, Castillo C, San L, del Moral E, Gonzalez ML, de la Torre R (1998) Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend 52:193–200

    Article  PubMed  CAS  Google Scholar 

  21. Gibaldi M, Perrier D (1982) Appendix D. Estimation of areas. In: Pharmacokinetics. Marcel Dekker, New York, pp 445–449

  22. Kharasch ED, Hoffer C, Whittington D, Sheffels P (2004) Role of hepatic and intestinal cytochrome P4503A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250–269

    Article  PubMed  CAS  Google Scholar 

  23. Crettol S, Déglon JJ, Besson J et al (2005) Methadone enantiomer plasma levels CYP2B6, CYP2C19, CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604

    Article  PubMed  CAS  Google Scholar 

  24. Faucette SR, Zhang TC, Moore R et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72–80

    Article  PubMed  CAS  Google Scholar 

  25. Otero MJ, Fuertes A, Sánchez R, Luna G (1999) Nevirapine induced withdrawal symptoms in HIV patients on methadone maintenance programmes—an alert. AIDS 13:1004–1005

    Article  PubMed  CAS  Google Scholar 

  26. Barry M, Feely J (1990) Enzyme induction and inhibition. Pharmacol Ther 48:71–94

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was sponsored by Boehringer Ingelheim. We acknowledge the development of the sample analysis to the Pharmacology Department of the Instituto Municipal de Investigación (IMIN, Barcelona, Spain). We also acknowledge Prof. Ricardo Nalda-Molina for critical review of the statistical treatment of pharmacokinetic data.

Author information

Authors and Affiliations

  1. Pharmacy Service, Hospital General Universitario de Alicante, Alicante, Spain

    Elena Arroyo & Eduardo Climent-Grana

  2. Pharmacy and Pharmaceutics Division, Department of Engineering, Faculty of Pharmacy, Miguel Hernández University, San Juan de Alicante, Alicante, Spain

    Elena Arroyo, Belén Valenzuela, Eduardo Climent-Grana & Juan José Pérez-Ruixo

  3. Unit of Infectious Diseases, Hospital General Universitario de Alicante, Alicante, Spain

    Joaquín Portilla & Esperanza Merino

  4. AVDA, Fabraquer no 34 E, 03560 El Campello, Alicante, Spain

    Elena Arroyo

Authors
  1. Elena Arroyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Belén Valenzuela
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joaquín Portilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eduardo Climent-Grana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan José Pérez-Ruixo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Esperanza Merino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elena Arroyo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arroyo, E., Valenzuela, B., Portilla, J. et al. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol 63, 669–675 (2007). https://doi.org/10.1007/s00228-007-0299-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0299-z

Keywords

Search

Navigation